Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

LONDON: Doctors worldwide should diagnose obesity differently, relying on broader criteria and taking into account when the condition causes ill-health, according to a new framework drawn up by ...

Gov. Newsom in 2020 signed a law allowing California to manufacture its own insulin, an effort to bring down the cost of the ...

Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...

Baltimore's school board joined districts across the country in suing drug makers over the skyrocketing costs of diabetes ...

Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment," at 4:40 p.m. ET, and in a subsequent update, incorrectly ...

The Dow, S&P 500, and Nasdaq rally Wednesday as the stock market digests the latest CPI inflation report and earnings from several big U.S. banks.